Combination Study of SV-BR-1-GM With Retifanlimab
Breast Cancer · Breast Neoplasm · Metastatic Breast Cancer · Breast Cancer Metastatic
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 36 (final count)
- Started
- Mar 16, 2018
- Main results expected
- Mar 24, 2026
- Fully finished
- Mar 24, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Evaluate the Adverse Events (AEs), including Serious Adverse Events (SAEs), that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab) [Safety]
Measured over: Through study completion, an average of 1 year
Evaluate the Proportion of Patients with Abnormalities in Safety Laboratory Parameters that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab) [Safety]
Measured over: Through study completion, an average of 1 year
Evaluate changes in the electrocardiogram QT interval that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab)[Safety]
Measured over: Through study completion, an average of 1 year
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03328026 · record last updated 2026-03-27 · checked 2026-11-09 15:42 UTC